Emergex Vaccines has secured a grant of almost £1 million from Innovate UK to advance its universal flu vaccine programme through preclinical development.
This grant will cover 70% of the cost of developing the programme over a period of two years. It will be used to complete preclinical toxicology and validation studies and the manufacturing of the vaccine in accordance with current Good Manufacturing Practice (cGMP).
This will result in clinical batches of the vaccine which are ready for Phase I clinical testing in the first half of 2020.
Emergex’s universal flu vaccine is designed to target components of the influenza virus that are common to all influenza strains. As a result, the vaccine will also be suitable to target the outbreak of a new flu pandemic caused by the emergence of a novel form of influenza virus at the time it moves from an animal species into humans.
The vaccine is 100% synthetic and delivers highly conserved immunogenic peptide fragments from the flu virus to antigen presenting cells in the skin, eliciting a strong and long-lasting T-cell immune response.
The UK government risk register has identified pandemic flu as one of one of the most severe natural challenges likely to affect the UK over the next few years. A recent World Health Organisation model predicts that pandemic flu could kill an estimated 720,000 people per year and result in economic losses of over 500 billion.
Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex, said: “This Innovate UK grant provides endorsement of our flu vaccine programme and reinforces our belief that an innovative approach, using the very latest technologies, could help protect the public from this inevitable epidemic or pandemic health threat.”
In addition to developing a universal flu vaccine, Emergex is also developing a universal Flavivirus vaccine which is cross reactive against Zika, Dengue and Yellow Fever, and a universal Filovirus vaccine which is cross reactive against Ebola and Marburg virus.